Loading...
XNYS
ENOV
Market cap1.92bUSD
Jun 10, Last price  
33.55USD
1D
2.01%
1Q
-7.78%
Jan 2017
-6.62%
IPO
63.66%
Name

Enovis Corp

Chart & Performance

D1W1MN
P/E
P/S
0.91
EPS
Div Yield, %
Shrs. gr., 5y
3.95%
Rev. gr., 5y
-8.73%
Revenues
2.11b
+23.46%
345,478,000393,604,000506,305,000604,854,000525,024,000541,987,000693,392,0003,913,856,0004,207,209,0004,624,476,0003,967,053,0003,647,047,0003,300,184,0003,666,812,0003,327,458,0003,070,769,0003,854,303,0001,563,101,0001,707,197,0002,107,623,000
Net income
-825m
L+2,381.87%
12,247,00094,00064,882,000-571,00021,722,00016,215,0004,555,000-64,402,000178,628,000392,098,000167,739,000128,111,000151,090,000140,196,00018,863,00064,082,00098,693,000-38,189,000-33,261,000-825,494,000
CFO
114m
-15.92%
-7,754,000-17,355,00074,483,000-31,513,00038,286,00061,965,00057,153,000164,299,000362,169,000385,758,000303,813,000246,974,000218,770,000226,367,000130,948,000301,935,000356,099,000-55,861,000134,988,000113,504,000
Earnings
Aug 05, 2025

Profile

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. Colfax Corporation was founded in 1860 and is headquartered in Wilmington, Delaware.
IPO date
May 08, 2008
Employees
16,200
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,107,623
23.46%
1,707,197
9.22%
1,563,101
-59.45%
Cost of revenue
1,018,165
791,749
754,545
Unusual Expense (Income)
NOPBT
1,089,458
915,448
808,556
NOPBT Margin
51.69%
53.62%
51.73%
Operating Taxes
4,492
(13,289)
36,120
Tax Rate
0.41%
4.47%
NOPAT
1,084,966
928,737
772,436
Net income
(825,494)
2,381.87%
(33,261)
-12.90%
(38,189)
-138.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,874
1,776
5,814
BB yield
-0.08%
-0.06%
-0.20%
Debt
Debt current
13,798
21,568
219,279
Long-term debt
157,383
585,100
142,518
Deferred revenue
Other long-term liabilities
1,520,528
204,178
166,989
Net debt
123,014
570,477
321,002
Cash flow
Cash from operating activities
113,504
134,988
(55,861)
CAPEX
(180,714)
(122,223)
(105,450)
Cash from investing activities
(955,473)
(242,467)
(176,388)
Cash from financing activities
846,821
127,797
(465,127)
FCF
861,879
767,640
1,268,829
Balance
Cash
48,167
36,191
24,295
Long term investments
16,500
Excess cash
Stockholders' equity
(408,792)
519,954
524,072
Invested Capital
4,618,598
4,161,295
3,913,652
ROIC
24.71%
23.00%
13.76%
ROCE
25.88%
22.00%
20.66%
EV
Common stock shares outstanding
55,291
54,495
54,065
Price
43.88
-21.67%
56.02
4.67%
53.52
16.42%
Market cap
2,426,167
-20.53%
3,052,800
5.50%
2,893,581
23.08%
EV
2,551,248
3,625,586
3,216,299
EBITDA
1,374,254
1,132,548
1,028,266
EV/EBITDA
1.86
3.20
3.13
Interest
57,100
19,749
24,052
Interest/NOPBT
5.24%
2.16%
2.97%